Opinion

Video

T-DXd in Advanced Endometrial Cancer

Author(s):

Angeles Alvarez Secord, MD, MHSc ,Dana M. Chase, MD, FACOG

Panelists discuss the recent tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) based on findings from the DESTINY-PanTumor02 trial, exploring its implications for treatment approaches in advanced endometrial cancer, how to integrate T-DXd into treatment algorithms, patient selection criteria, and which patients are most likely to benefit from this therapy compared to lenvatinib/pembrolizumab.

Video content above is prompted by the following:

  • Briefly comment on the recent tumor agnostic approval for trastuzumab deruxtecan (T-DXd) based on the findings from DESTINY-PanTumor02.
  • How will this impact your treatment approach for patients with advanced endometrial cancer?
  • Where will you integrate T-DXd into your treatment algorithm, how will you select patients for treatment, and which patients are most likely to benefit from this treatment approach?
  • Talking points: T-DXd compared with use of lenvatinib/pembrolizumab
Related Videos
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment